A clinical trial called the SPECIAL study is investigating the safety and efficacy of the PCSK9 inhibitor evolocumab in patients with non‐ST segment elevation acute coronary syndrome (NSTE‐ACS) and multivessel CAD who have undergone culprit vessel revascularization [34]. Here, PCSK9 is linked to coronary artery disorder.